Australia markets closed

Beximco Pharmaceuticals Limited (R2WA.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
0.43600.0000 (0.00%)
At close: 08:20AM CET
Show:
Annual

Income statement

Currency in BDT. All numbers in thousands
Breakdown
ttm
30/06/2023
30/06/2022
30/06/2021
30/06/2020
Total revenue
41,651,500
39,266,662
34,669,172
29,493,574
25,611,948
Cost of revenue
23,408,740
21,953,290
18,848,962
15,570,072
13,712,848
Gross profit
18,242,760
17,313,372
15,820,210
13,923,502
11,899,100
Operating expenses
Research development
188,282
364,419
260,151
234,683
180,947
Selling general and administrative
5,299,580
4,814,992
4,234,815
3,638,762
3,180,431
Total operating expenses
10,642,848
10,139,676
8,974,052
7,264,092
6,384,544
Operating income or loss
7,599,912
7,173,696
6,846,158
6,659,411
5,514,556
Interest expense
1,168,875
1,241,660
925,596
805,874
983,200
Income before tax
6,433,468
6,068,769
6,686,945
6,377,548
4,653,440
Income tax expense
1,558,923
1,544,300
1,688,317
1,211,798
1,108,957
Income from continuing operations
4,874,544
4,524,468
4,998,628
5,165,750
3,544,483
Net income
4,916,418
4,614,066
5,123,137
5,127,694
3,514,687
Net income available to common shareholders
4,916,418
4,614,066
5,123,137
5,127,694
3,514,687
Basic EPS
10.34
10.34
11.48
11.49
7.88
Diluted EPS
10.34
10.34
11.48
11.49
7.88
Basic average shares
446,112
446,112
446,112
446,112
446,112
Diluted average shares
446,112
446,112
446,112
446,112
446,112